Proteasomes are molecular machines found in every cell of your body whose primary job is to chew up proteins that are no longer needed, damaged, or potentially dangerous. They are not passive recyclers sitting in a corner; they actively regulate nearly every major cellular process, from how cells divide to how the immune system recognizes threats. Because cancer cells rely on proteasomes even more heavily than healthy cells do, drugs that block these machines have become a genuine treatment for certain blood cancers and a springboard for an expanding class of targeted therapies.
A Barrel-Shaped Protein Shredder
The core of the proteasome is a hollow cylinder called the 20S core particle, built from 28 protein subunits arranged in four stacked rings. Think of it as a barrel with cutting blades on the inside walls. Three of those inner subunits handle the actual protein-chopping work, each one specializing in cutting next to different types of amino acids.
On its own, the 20S core can degrade certain proteins, but the full workhorse version used for most regulated protein destruction is the 26S proteasome. This is the 20S barrel capped on one or both ends by a 19S regulatory particle, a multi-protein complex that acts as a gatekeeper. The 19S cap recognizes proteins tagged for destruction, unfolds them from their three-dimensional shapes, and threads them into the barrel’s interior. This unfolding step is powered by a ring of six energy-consuming subunits that use ATP to mechanically pull and push the doomed protein through a narrow channel. Structural studies have captured this motor in multiple positions, revealing that it works in a hand-over-hand fashion, with different subunits firing in sequence to drive the substrate forward like a ratchet.
The threading is directional. Experiments attaching bulky molecular tags to different ends of a test protein showed that the substrate gets fed through the motor in a specific orientation; attaching a large obstacle near the trailing end blocked translocation entirely, even though the motor still unfolded the protein on its outer surface.
How Proteins Get Tagged for Destruction
Cells do not randomly feed proteins into proteasomes. A tagging system marks specific proteins with a small protein called ubiquitin. The process works through a cascade of three enzyme types. An activating enzyme hands ubiquitin to a carrier enzyme, which then works with a ligase enzyme to attach ubiquitin directly to the target protein. Multiple ubiquitin molecules are linked together into a chain, and chains connected through a particular internal site on ubiquitin, known as lysine-48 linkage, serve as the best-characterized “destroy me” signal. Other chain types also play roles, but lysine-48 chains remain the canonical trigger for proteasomal degradation.
Once a tagged protein reaches the proteasome, it docks at receptor subunits on the 19S cap that preferentially grab lysine-48-linked chains. Before the protein enters the barrel, however, the ubiquitin tags are stripped off and recycled. Three distinct deubiquitinating enzymes handle this job. One clips the entire chain at its base where it attaches to the substrate, while the other two nibble ubiquitin molecules off from the far end of the chain. This recycling is efficient: ubiquitin is a small, valuable protein, and cells conserve it rather than shredding it alongside the condemned substrate.
Driving the Cell Cycle
Cell division depends on proteins appearing and disappearing at precisely the right moments. The proteasome is the disappearing act. Two major families of ubiquitin ligases, the SCF complex and the APC/C (sometimes called the cyclosome), orchestrate the timed destruction of key regulators that control when a cell copies its DNA and when it physically splits in two. The APC/C, for instance, triggers the breakdown of proteins that inhibit chromosome separation; without this step, a dividing cell cannot pull its duplicated chromosomes apart and complete division. The precision is extraordinary: the wrong protein degraded at the wrong time can stall division or, worse, allow a cell to divide with damaged DNA.
Protein Quality Control and the ER Connection
Your cells constantly produce proteins that fold incorrectly. These misfolded proteins can clump together and become toxic. The proteasome is a frontline defense against this buildup, but its role extends to a specific rescue operation tied to a cellular compartment called the endoplasmic reticulum, or ER, where many proteins are manufactured and folded.
When a protein in the ER fails to fold properly, the cell does not have degradation machinery inside the ER itself. Instead, the misfolded protein is recognized, pulled back across the ER membrane into the surrounding cell fluid, tagged with ubiquitin, and delivered to a nearby proteasome for destruction. This process, called ER-associated degradation, prevents the ER from clogging up with defective products. It also regulates certain normal proteins, including enzymes involved in cholesterol production, by controlling how quickly they are broken down.
Switching On Inflammation Through NF-κB
One of the most consequential things proteasomes do has nothing to do with garbage disposal and everything to do with cell signaling. A protein complex called NF-κB controls the expression of hundreds of genes involved in inflammation, immune responses, and cell survival. In resting cells, NF-κB is held hostage by an inhibitor protein called IκBα, which keeps it locked in the cytoplasm and unable to reach the nucleus where it would activate genes. When the cell receives a signal, such as encountering a pathogen or an inflammatory molecule, IκBα gets phosphorylated, tagged with ubiquitin, and rapidly destroyed by the proteasome. With its inhibitor gone, NF-κB is free to enter the nucleus and switch on its target genes.
Blocking this step with proteasome inhibitors prevents NF-κB activation, which is one reason these drugs have therapeutic effects beyond simply killing cancer cells. Early experiments showed that even micromolar concentrations of a proteasome-blocking compound could prevent NF-κB from turning on in response to inflammatory signals, by stabilizing the phosphorylated form of IκBα that would normally be destroyed.
The Immunoproteasome and Antigen Presentation
Your immune system’s ability to detect infected or cancerous cells hinges on proteasomes, but not the standard version. When cells are exposed to the signaling molecule interferon-gamma, typically during an infection, they swap out the three catalytic subunits in their proteasomes for a different trio of inducible subunits. The result is the immunoproteasome, a variant that cuts proteins differently, generating peptide fragments better suited for display on the cell surface by MHC class I molecules. These displayed fragments are what killer T cells scan to determine whether a cell is healthy or harboring something dangerous.
The immunoproteasome tends to produce peptides ending in particular amino acids that fit more snugly into the MHC groove, broadening the repertoire of fragments the immune system can inspect. Activating the immunoproteasome experimentally has been shown to expand the pool of displayed peptides, including fragments derived from mutated cancer proteins that the standard proteasome would not have generated efficiently. This has obvious implications for cancer immunology.
There is also a third variant, the thymoproteasome, found only in a specific type of cell in the thymus. It contains a unique catalytic subunit called β5t and produces a distinct set of peptides that help train developing CD8+ T cells during a process called positive selection. Variations in the gene encoding β5t influence which T cells survive this training, shaping the diversity of your immune repertoire before T cells ever encounter a pathogen.
Proteasome Failure in Neurodegeneration
If the proteasome is a cell’s waste-processing facility, neurodegenerative diseases look increasingly like the consequences of that facility breaking down. Conditions including Alzheimer’s, Parkinson’s, Huntington’s, and ALS all feature the toxic accumulation of misfolded, aggregation-prone proteins, and impaired proteasome function has been linked to each of them. The relationship is likely a vicious cycle: aggregated proteins can physically clog or impair proteasomes, and the resulting drop in protein-clearing capacity allows even more aggregates to build up. Oxidative stress, chronic inflammation, and the natural decline of proteasome activity with aging all compound the problem.
This has made boosting proteasome activity an appealing therapeutic idea. Researchers have explored genetic manipulations, post-translational modifications, and small molecules that could increase the rate at which proteasomes clear misfolded proteins, though translating these approaches into treatments remains an early-stage endeavor.
Why Cancer Cells Are Especially Vulnerable
Cancer cells live on the edge of a protein crisis. Their genomes are unstable, they often carry extra or abnormal chromosomes, and they churn out proteins at high rates. All of this generates a heavy load of misfolded and excess proteins that must be cleared to keep the cell alive. This elevated dependence on protein disposal makes cancer cells more sensitive to proteasome inhibition than normal cells, an observation that underpins an entire class of cancer drugs.
The idea is sometimes described as targeting the cancer cell’s Achilles’ heel: because cancer cells are already under more protein-folding stress than healthy cells, tipping the balance further by blocking the proteasome can push them into a lethal crisis while leaving normal cells relatively intact.
Proteasome Inhibitors in the Clinic
Bortezomib, the first proteasome inhibitor approved for clinical use, reached the market in 2003 for relapsed or refractory multiple myeloma, a cancer of antibody-producing blood cells that are especially burdened by protein production. It works by binding to the main catalytic subunit of the proteasome, blocking the chymotrypsin-like cutting activity and causing undegraded proteins to pile up inside the cell. This accumulation triggers cell death through multiple routes, including blocking NF-κB activation, disrupting cell-cycle progression, and inducing apoptosis. It was later approved for previously untreated myeloma and, in 2006, for mantle cell lymphoma.
Clinical results showed that bortezomib could induce responses even in patients who had stopped responding to other treatments, including those with high-risk genetic features in their cancer. However, it comes with side effects, the most troublesome being peripheral neuropathy, nerve damage that causes pain, tingling, or numbness in the hands and feet.
This limitation drove the development of second-generation proteasome inhibitors. Carfilzomib, approved in 2012, binds irreversibly to the proteasome rather than reversibly like bortezomib, and causes less peripheral neuropathy, though it carries its own cardiovascular risks. Ixazomib became the first oral proteasome inhibitor approved for myeloma, offering the convenience of a pill rather than an injection. Other compounds, including oprozomib and marizomib, have entered clinical testing with different pharmacological profiles and activity against bortezomib-resistant disease.
Resistance remains a challenge. Cancer cells can develop resistance to proteasome inhibitors through several routes, including mutations in the target subunit that reduce drug binding, increased expression of the subunit to compensate for partial blockade, and activation of alternative protein-disposal pathways. Laboratory models have shown cross-resistance among different proteasome inhibitors, meaning a tumor that becomes resistant to one drug often resists others in the same class.
Selective Immunoproteasome Inhibitors for Autoimmune Disease
Because the immunoproteasome plays a distinct role in immune signaling and inflammation, researchers have pursued drugs that block only the immunoproteasome’s unique subunits while leaving the standard proteasome intact. The hope is to dampen overactive immune responses in autoimmune diseases without the broader toxicity of blocking all proteasome function. Selective immunoproteasome inhibitors have shown broad anti-inflammatory activity in preclinical studies, and at least one compound, KZR-616, has reached clinical trials for systemic lupus erythematosus. This is a fundamentally different therapeutic philosophy from the myeloma drugs: rather than overwhelming a cancer cell with protein waste, the goal is to fine-tune immune peptide production and inflammatory signaling.
Hijacking the Proteasome With PROTACs
An entirely different approach does not block the proteasome but instead harnesses it to destroy specific disease-causing proteins that traditional drugs cannot target. PROTACs, short for proteolysis-targeting chimeras, are engineered molecules with two functional ends: one end grabs the disease protein, and the other end recruits a ubiquitin ligase enzyme. By bringing the two together, the PROTAC tricks the cell’s own tagging machinery into ubiquitinating the disease protein, which the proteasome then dutifully destroys. A related strategy uses molecular glues, smaller compounds that stabilize an interaction between a target protein and a ligase.
The appeal of this approach is that it can go after proteins previously considered “undruggable,” ones that lack the kind of binding pockets traditional drugs need. Because the PROTAC acts as a matchmaker rather than a blocker, it can work at low concentrations and is recycled after each round of destruction. Several PROTACs are in clinical trials for cancers driven by proteins that have resisted conventional drug development for decades.
Boosting Rather Than Blocking Proteasome Activity
While most medical attention has focused on inhibiting proteasomes, a growing line of research asks the opposite question: can you crank proteasome activity up? For diseases characterized by toxic protein accumulation, such as the neurodegenerative conditions discussed earlier, enhancing the cell’s protein-clearing capacity could be beneficial.
One experimental route involves inhibiting a signaling enzyme called p38 MAPK. Blocking this enzyme with small molecules increased proteasome activity in a dose-dependent manner in cell experiments, boosting the function of multiple catalytic subunits without changing the amount of proteasome protein in the cell. The effect was consistent across several structurally different p38 inhibitors, suggesting it reflects a genuine regulatory relationship rather than an off-target artifact. Other approaches being explored include genetic overexpression of proteasome subunits and compounds that open the gate of the 20S core to allow faster substrate entry. None of these strategies has reached patients yet, but they represent a conceptual shift in how the proteasome is viewed therapeutically.
Proteins That Skip the Ubiquitin Tag
The textbook pathway says proteins must be tagged with ubiquitin to be recognized and destroyed by the proteasome. That is true for most regulated degradation, but a significant exception exists. A class of proteins known as intrinsically disordered proteins, which lack stable three-dimensional structure, can be degraded directly by the 20S core particle without ubiquitin tagging and without the 19S cap’s involvement. Because these proteins are already unfolded or loosely structured, they can slip into the barrel’s central chamber on their own.
This pathway is regulated by protective binding partners, sometimes called “nannies,” and by an enzyme called NQO1 that associates with the 20S proteasome and shields certain disordered proteins from premature destruction. Intrinsically disordered proteins include important regulatory molecules such as the tumor suppressor p53 and the cell-cycle inhibitor p21, meaning this ubiquitin-independent pathway is not a minor footnote but a significant regulatory mechanism in its own right. Research has shown a positive correlation between the degree of structural disorder in a protein and its susceptibility to 20S proteasomal degradation.
Proteasomes Under Stress
Proteasomes are not bolted in place. Their location inside the cell shifts depending on conditions. During normal growth in yeast, proteasomes are concentrated in the nucleus. When cells enter a resting state called quiescence, proteasomes relocate to the cytoplasm and cluster into dense granules called proteasome storage granules. These granules are reversible and depend on ubiquitin signaling for their formation. When nutrients return, the granules dissolve and proteasomes redistribute back to their active locations.
In mammalian cells, various stress conditions also drive proteasome redistribution into membraneless granules in either the nucleus or the cytoplasm. The functional significance of this clustering is still being worked out, but it appears to serve as a form of cellular resource management, parking proteasomes in a protected state during conditions when the cell’s energy is better spent elsewhere, while keeping them available for rapid reactivation.
Assembly From Scratch
Building a proteasome is not simple. The 20S core particle alone requires 28 subunits to find each other and assemble in the correct order. Cells do not leave this to chance. At least five dedicated chaperone proteins guide the process, shepherding subunits through intermediate stages of assembly. Recent structural studies using cryo-electron microscopy have captured snapshots of these intermediates, showing that the outer-ring subunits undergo substantial movements as the inner-ring subunits are added, while the chaperones themselves make mostly local adjustments. Once the barrel is fully assembled, the chaperones are cleared and the catalytic subunits undergo a final maturation step that activates their cutting ability. The chaperones themselves are then degraded, partly by the very proteasome they just helped build.